Cymabay Therapeutics, Inc. (CBAY): Charles Mcwherter , Sr. Vice President of Cymabay Therapeutics, Inc. purchased 3,000 shares on Apr 15, 2016. The Insider buying transaction was reported by the company on Apr 19, 2016 to the Securities and Exchange Commission. The shares were purchased at $1.68 per share for a total value of $5,040.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 6, 2016, Sujal Shah (CFO) purchased 55,000 shares at $1.39 per share price.On Sep 11, 2015, Carl Goldfischer (director) sold 46,729 shares at $2.74 per share price.Also, On Aug 17, 2015, Emster Kurt Von (director) purchased 90,000 shares at $2.69 per share price.On May 19, 2015, Charles Mcwherter (Sr. Vice President) purchased 2,000 shares at $3.16 per share price.
CymaBay Therapeutics Inc: On Monday, Apr 18, 2016 heightened volatility was witnessed in CymaBay Therapeutics Inc which led to swings in the share price. The shares opened for trading at $1.65 and hit $1.81 on the upside , eventually ending the session at $1.69, with a gain of 3.68% or 0.06 points. The heightened volatility saw the trading volume jump to 6,90,880 shares. The 52-week high of the share price is $5.72 and the company has a market cap of $40 M . The 52-week low of the share price is at $0.8201.
Currently the company Insiders own 10.7% of CymaBay Therapeutics Inc shares according to the proxy statements.Institutional Investors own 45.89% of CymaBay Therapeutics Inc shares.
CymaBay Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases including serious rare and orphan disorders. Arhalofenate the Company’s lead product candidate is used to treat gout. The Company has completed five Phase II clinical trials of Arhalofenate in patients with gout. The Company’s second product candidate MBX-8025 is used to treat disorder linked to deficits in lipid storage handling and utilization many of which result in metabolic disorders. The Company has completed five Phase I and one Phase II clinical trials of MBX-8025. The Company’s MBX-2982 is a treatment for type 2 diabetes that targets G protein-coupled receptor 119 (GPR119) a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion. MBX-2982 has completed four Phase I studies and one Phase II study.